NMN Supplement Research, Safety, and Trial Results

Human Trial Findings on NMN

Published human clinical trials evaluate oral NMN at daily doses between 100 and 2000 mg, with 250 mg daily serving as the most frequently tested regimen. In the 2023 review by Song and colleagues, ten human clinical trials were published, 13 were completed but unpublished, and 11 were ongoing. Eight of the trials enrolled 8 to 66 participants, focusing primarily on older adults. The documented outcomes from these human clinical trials include the following findings:

• Circulating NAD+ levels: NMN raised blood NAD+ in several human trials.
• Muscle insulin sensitivity: In a trial of 25 postmenopausal women with prediabetes receiving 250 mg daily for 10 weeks, skeletal muscle insulin sensitivity improved by 25 ± 7%. Skeletal muscle NAD+ concentrations did not increase in this specific cohort.
• Physical performance: Trials observed higher aerobic capacity among recreationally trained runners, as well as improvements in walking endurance and lower-limb function tests in older adults.
• Unchanged metrics: Human trials found no statistically significant alterations in overall blood pressure or blood glucose levels.
• Other measures: Sleep quality and ophthalmic measures did not change.

NMN Mechanism and Relationship to NAD+

Nicotinamide mononucleotide is an immediate biochemical precursor to nicotinamide adenine dinucleotide (NAD+). NAD+ is a coenzyme in redox reactions and a cofactor for sirtuins and PARPs. The exact mechanism by which exogenous NMN enters human cells remains subject to ongoing scientific debate. The more widely accepted route is conversion to nicotinamide riboside outside the cell. It then converts back to NMN inside it.

NMN occurs naturally in some foods in small amounts. Published analyses report vegetable concentrations ranging from 0.035 to 1.88 mg per 100 g. Fresh fruits contain between 0.021 and 1.6 mg per 100 g. Typical total dietary intake of naturally occurring NMN is estimated at 2 mg daily or less. Scientific literature reports progressive reductions of NAD+ in human skin, blood, liver, skeletal muscle, and brain tissue. Specifically, two human magnetic resonance imaging (MRI) studies documented that brain NAD+ concentrations fell by 10% to 25% between young adulthood and old age. Despite these documented reductions, researchers note that the medical field lacks consensus regarding what values constitute high, adequate, or deficient NAD+ levels in human blood or tissue. Blood or tissue NAD+ is not yet validated as a status or disease-risk marker.

NMN Safety and Toxicity Findings

The authors conclude oral NMN is generally safe, with limited indicators studied. A single dose of up to 500 mg was safe and well tolerated in a 10-man trial. Across multiple-dose investigations, the highest dosage evaluated in published literature reached 1000 mg administered twice daily over 14 consecutive days. No side effects of NR or NMN had been shown in human trials so far. There is currently no established tolerable upper intake level for NMN or NR established by dietary authorities.

Animal and cell models raise hypothetical concerns:

• Axon degeneration: Worse axon degeneration occurred in a chemotherapy-neuropathy mouse model.
• Pro-inflammatory senescence and oncogenesis: Enhanced pro-inflammatory senescence signaling and pancreatic cancer progression occurred in a Kras mouse model.

These are not human findings. Additional context on cellular compounds appears in our guide on NAD+ therapy and our broader review of longevity supplements.

Legal Status of NMN in the United States

The United States regulatory status of NMN has changed by the Food and Drug Administration (FDA). On November 10, 2022, the FDA declared beta-NMN prohibited as a supplement. On September 29, 2025, the FDA issued two formal letters confirming that NMN is not excluded from the statutory definition of a dietary supplement, effectively reversing the agency's earlier prohibition. As detailed in the Venable regulatory analysis, NMN remains classified as a New Dietary Ingredient (NDI). Consequently, each company marketing NMN must file a New Dietary Ingredient Notification. This is required unless sourcing from a supplier that already filed. Self-affirmed Generally Recognized as Safe (GRAS) determinations do not satisfy this requirement. The FDA's position remains subject to future legal challenge. The FDA has issued no guidance on the drug-exclusion exception.

Limits of the Current Clinical Evidence

Current human evidence has clear limits. Most published trials have evaluated small participant cohorts with 8 to 66 participants in eight studies, with study populations composed mostly of older adults. Long-term safety is unknown. Safe dose ranges are unknown. No dietary reference intake exists for NMN.Few indicators were measured. Skin claims lack human clinical evidence. More trials are needed.

Clinical Considerations for Readers

Whether to take any supplement is for the reader's clinician. This is critical with cancer, kidney disease, or medicines.